Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brown syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Brown syndrome. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-001045-12 Sponsor Protocol Number: APH205 Start Date*: 2021-09-22
    Sponsor Name:Asarina Pharma ApS
    Full Title: A randomized, open-label, multicenter, phase 2 clinical trial to explore the safety and efficacy of sepranolone in pediatric and adult patients with Tourette Syndrome.
    Medical condition: Tourette Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018269 Gilles de la Tourette syndrome LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001694-24 Sponsor Protocol Number: D1050302 Start Date*: 2014-03-11
    Sponsor Name:SUNOVION PHARMACEUTICALS INC.
    Full Title: A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT...
    Medical condition: SCHIZOPHRENIA AND IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) IT (Prematurely Ended) BG (Completed) Outside EU/EEA HU (Completed) GB (Completed) DE (Completed) PL (Completed) BE (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-000942-39 Sponsor Protocol Number: NL34476.068.11 Start Date*: 2011-06-20
    Sponsor Name:CTMM, the Center for Translational Molecular Medicine
    Full Title: Effects of thyroid hormone treatment on mitochondrial function, ectopic fat accumulation, insulin sensitivity and brown adipose tissue in type 2 diabetes mellitus.
    Medical condition: This trial includes overweight patients with both hypothyroidism and type 2 diabetes.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10014698 - Endocrine disorders 10021114 Hypothyroidism PT
    13.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000342-32 Sponsor Protocol Number: 248.642 Start Date*: 2009-02-17
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: An open-label, flexible dose, follow-up study to evaluate safety and efficacy of oral pramipexole (0.0625-0.5 mg/day) for 24 weeks in children and adolescents (age 6-17 years) diagnosed with Touret...
    Medical condition: Tourette's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10044127 Tourette's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-001723-12 Sponsor Protocol Number: ARIVA_venous Start Date*: 2020-05-28
    Sponsor Name:Universitätsspital Zürich, Klinik für Angiologie
    Full Title: Aspirin® plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis in patients with post-thrombotic syndrome
    Medical condition: Post-thrombotic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000014-38 Sponsor Protocol Number: THX-G18-001 Start Date*: 2018-08-02
    Sponsor Name:Therapix Biosciences Ltd.
    Full Title: A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study to Evaluate the Safety, Tolerability and Efficacy of Daily Oral THX-110 in Treating Adults with Tourette Syndrome (“ENTOURAGE”)
    Medical condition: Tourette Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10044127 Tourette's syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000612-26 Sponsor Protocol Number: FINTOURPARK Start Date*: 2011-09-19
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
    Full Title: Open-label study on the use of Finasteride in prolonged treatment (4 years) of tics in Tourette's disease and Parkinson's disease in the pounding
    Medical condition: Syndrome Gilles de la Tourette's disease Parkinosn Pounding
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000564-42 Sponsor Protocol Number: CANNA-TICS Start Date*: 2017-06-14
    Sponsor Name:Hannover Medical School
    Full Title: A randomized multi-centre double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders (CANNA-TICS)
    Medical condition: Chronic tic disorders and Tourette syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10043835 Tic disorders HLT
    20.0 100000004850 10018269 Gilles de la Tourette syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002778-38 Sponsor Protocol Number: CL2-78989-012 Start Date*: 2013-11-11
    Sponsor Name:Institut de Recherches Internationales Servier (IRIS)
    Full Title: A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritis
    Medical condition: Giant cell arteritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Completed) GB (Completed) CZ (Completed) FI (Completed) DK (Prematurely Ended) BE (Completed) AT (Completed) IE (Prematurely Ended) EE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004460-39 Sponsor Protocol Number: 248.644 Start Date*: 2008-11-11
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.0625-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age...
    Medical condition: Tourette's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10044127 Tourette's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002430-36 Sponsor Protocol Number: AntibioTICS Start Date*: 2012-07-02
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Multicentre, randomised, double-blinded, placebo-controlled trial of efficacy of amoxicilline/clavulanic acid in patients affected by tic disorder colonized by GAS. No-proft stidy.
    Medical condition: Chronic tic disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10043834 Tic disorder, unspecified LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008339-27 Sponsor Protocol Number: A0081107 Start Date*: 2009-05-07
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY10017
    Full Title: A 17-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF CHRONIC CENTRAL NEUROPATHIC PAIN AFTER SPINAL CORD INJURY
    Medical condition: Chronic Central Neuropathic Pain after Spinal Cord Injury.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-000419-98 Sponsor Protocol Number: B4Z-US-LYEI Start Date*: 2021-12-13
    Sponsor Name:Eli Lilly and Company
    Full Title: Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tas...
    Medical condition: Attention Deficit Hyperactivity Disorder, Dyslexia.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    20.0 10029205 - Nervous system disorders 10013932 Dyslexia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002822-21 Sponsor Protocol Number: ARCHIE001 Start Date*: 2013-10-10
    Sponsor Name:University of Oxford
    Full Title: The early use of Antibiotics for at Risk CHildren with InfluEnza in primary care (ARCHIE): a double-blind randomised placebo-controlled trial
    Medical condition: Influenza or influenza-like illness
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002716-41 Sponsor Protocol Number: ML39425 Start Date*: 2017-05-24
    Sponsor Name:ROCHE SAS
    Full Title: AN EXTENSION STUDY TO EVALUATE LONG TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH GIANT CELL ARTERITIS WHO HAVE COMPLETED WA28119 CORE STUDY IN FRANCE, AND SUBSEQUENTLY HAVING FLARE OR P...
    Medical condition: Giant cell arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005090-22 Sponsor Protocol Number: 001 Start Date*: 2012-02-28
    Sponsor Name:Southend Hospital
    Full Title: A study of efficacy and safety of delayed release prednisone in newly diagnosed cases of Giant Cell Arteritis
    Medical condition: Giant Cell Arteritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-002826-22 Sponsor Protocol Number: BONNOTTE-PHRCN-2017 Start Date*: 2019-03-07
    Sponsor Name:CHU Dijon Bourgogne
    Full Title: MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender:
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002622-24 Sponsor Protocol Number: CAIN457R1DE01 Start Date*: 2022-06-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, parallel-group, double-blind, placebo-controlled, multicenter trial to investigate the efficacy and safety of subcutaneously administered secukinumab in patients with new-onset of gia...
    Medical condition: Giant Cell Arteritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10047065 - Vascular disorders 10018250 Giant cell arteritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000622-26 Sponsor Protocol Number: CNTO1959GCA2001 Start Date*: 2020-12-07
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants with New-Onset or Relapsing Giant Cell Arteritis
    Medical condition: Giant Cell Arteritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Completed) PL (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020404-29 Sponsor Protocol Number: H9V-MC-GFRF Start Date*: 2011-04-08
    Sponsor Name:Eli Lilly and Company Limited, Indianapolis
    Full Title: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients with Diabetic Kidney Disease due to Type 1 or Type 2 D...
    Medical condition: Patients with Diabetic Kidney Disease due to Type 1 or Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 31 00:52:17 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA